FDA Approves RSV Vaccine Abrysvo for Use During Pregnancy to Protect Infants
Abyrsvo is the first vaccine approved for pregnant individuals to prevent RSV disease in infants.
Abyrsvo is the first vaccine approved for pregnant individuals to prevent RSV disease in infants.
Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period.
Aponvie is an injectable emulsion formulation of aprepitant.
Zurzuvae is expected to become available in the fourth quarter of 2023 following scheduling as a controlled substance by the DEA.
In their statement, the GI specialists noted that they are familiar with safety issues regarding endoscopy in patients with gastroparesis.
Semaglutide is a GLP-1 receptor agonist.
Ulotaront is a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity.
Each RiVive nasal spray unit contains 3mg of naloxone HCl and delivers a single dose.
Beyfortus is a long-acting anti-RSV monoclonal antibody.
Wegovy is a glucagon-like peptide-1 receptor agonist.